We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+12.08%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$265M
Cap. Flow
+$241M
Cap. Flow %
19.9%
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
17
Reduced
10
Closed
19

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$162M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
3
ONC
BeOne Medicines Ltd
ONC
+$52.3M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$45.9M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$42.7M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$58.1M
2
MRK icon
Merck
MRK
+$43.6M
3
CBAY
Cymabay Therapeutics
CBAY
+$38.4M
4
PCRX icon
Pacira BioSciences
PCRX
+$34.4M
5
PCVX icon
Vaxcyte
PCVX
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
26
Praxis Precision Medicines
PRAX
$9.9B
$12.8M 1.06%
+210,000
New +$9.42M
IMTX icon
27
Immatics
IMTX
$1.3B
$12.6M 1.04%
1,200,000
-900,000
-43% -$10.5M
INCY icon
28
Incyte
INCY
$24.3B
$11.4M 0.94%
+200,000
New +$12M
MGNX icon
29
MacroGenics
MGNX
$252M
$10.7M 0.88%
+725,000
New +$11M
AGIO icon
30
Agios Pharmaceuticals
AGIO
$1.9B
$9.5M 0.79%
+325,000
New +$8.7M
SWAV
31
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$8.14M 0.67%
+25,000
New +$6.14M
KRYS icon
32
Krystal Biotech
KRYS
$9.6B
$8.01M 0.66%
+45,000
New +$6.25M
KALV
33
DELISTED
KalVista Pharmaceuticals
KALV
$7.77M 0.64%
+655,000
New +$8.73M
GERN icon
34
Geron
GERN
$969M
$7.26M 0.6%
+2,200,000
New +$4.93M
ACLX
35
DELISTED
Arcellx
ACLX
$6.96M 0.58%
100,000
+40,000
+67% +$2.54M
EXAS
36
DELISTED
Exact Sciences
EXAS
$6.91M 0.57%
+100,000
New +$6.33M
FULC icon
37
Fulcrum Therapeutics
FULC
$289M
$6.56M 0.54%
695,000
-330,000
-32% -$2.95M
VKTX icon
38
Viking Therapeutics
VKTX
$3.89B
$6.15M 0.51%
+75,000
New +$3.34M
PASG icon
39
Passage Bio
PASG
$14.6M
$6.08M 0.5%
+225,000
New +$5.41M
ALLO icon
40
Allogene Therapeutics
ALLO
$683M
$6.03M 0.5%
+1,350,000
New +$5.63M
FATE icon
41
Fate Therapeutics
FATE
$294M
$5.87M 0.49%
800,000
-490,000
-38% -$3.03M
VYGR icon
42
Voyager Therapeutics
VYGR
$198M
$5.59M 0.46%
+600,000
New +$5.07M
RLMD icon
43
Relmada Therapeutics
RLMD
$540M
$5.58M 0.46%
1,200,000
+1,085,000
+943% +$5.23M
BIO icon
44
Bio-Rad Laboratories Class A
BIO
$9.21B
$5.19M 0.43%
+15,000
New +$4.93M
RARE icon
45
Ultragenyx Pharmaceutical
RARE
$2.52B
$5.14M 0.42%
+110,000
New +$5.19M
LYRA
46
DELISTED
LYRA THERAPEUTICS INC
LYRA
$4.98M 0.41%
16,000
-44,000
-73% -$11.7M
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.76B
$4.19M 0.35%
130,000
– –
ANRO icon
48
Alto Neuroscience
ANRO
$1.11B
$3.84M 0.32%
+250,000
New +$3.91M
LXEO icon
49
Lexeo Therapeutics
LXEO
$360M
$2.74M 0.23%
+175,000
New +$2.74M
PRME icon
50
Prime Medicine
PRME
$549M
$2.52M 0.21%
360,000
+339,694
+1,673% +$2.58M
1
2
3 4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
U
Uber San Francisco, California $3.6B AUM 19.81% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return

Vestal Point Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Vestal Point Capital held 77 positions worth $1.21B, up 28% from $944M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vestal Point Capital deployed $241M of net new capital in Q1 2024, opening 29 new positions and adding to 17 existing holdings. Its largest new stake was BeOne Medicines Ltd: 325,000 shares worth $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $34.4M trimmed.

  • Vestal Point Capital's largest Q1 2024 buy was BeOne Medicines Ltd: 325,000 shares worth $50.8M.
  • Vestal Point Capital added most to Cytokinetics in Q1 2024, an estimated $162M increase.
  • Vestal Point Capital's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $34.4M.
  • Vestal Point Capital fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $58.1M.
  • Vestal Point Capital's ten largest holdings make up 62% of its $1.21B portfolio in Q1 2024.
  • Vestal Point Capital opened 29 new positions and closed 19 in Q1 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.21B.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.